Ling Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ling Su has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Xiangguo Liu
Shandong University
32 shared publications Xianfang Liu
The Department of Otolaryngology Head and Neck Surgery, Shandong Provincial Hospital, Affiliated to Shandong University, Jinan, China
7 shared publicationsXiaopeng Li
Shandong Provincial Key Laboratory of Development and Regeneration, School of Life Sciences, Shandong University, Qingdao, China
6 shared publications- Yingying Wang
Shandong Provincial Key Laboratory of Development and Regeneration, School of Life Sciences, Shandong University
6 shared publications Yingying Wang
Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China
5 shared publicationsZhiyuan Du
Shandong Provincial Key Laboratory of Development and Regeneration, School of Life Sciences, Shandong University, Qingdao, China
5 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (37)
Tmem216 deficiency induces hydrocephalus via impaired ciliogenesis and disrupted ependymal planar polarity in mice
Defects in multiciliated ependymal cells (ECs), which line the cerebral ventricular walls and generate unidirectional cerebrospinal fluid (CSF) flow through coordinated ciliary beating, can lead to CSF accumulation and hydrocephalus. TMEM216 , a ciliopathy-associated gene mutated in Joubert, Meckel, and related syndromes, encodes an essential component of the protein complexes that form the transition zone (TZ) at the base of primary cilia. Here, we demonstrate that central nervous system-specific inactivation of Tmem216 results in severe postnatal hydrocephalus. TMEM216 localizes to the TZ of motile cilia in ECs and the TZ of primary cilia in radial glia cells (RGCs), the embryonic precursors of ECs. While Tmem216 -deficient ECs differentiate normally, TZ structure and ciliogenesis in both ECs and RGCs are severely disrupted, as shown by reduced cilia abundance and disrupted ciliary ultrastructure. These defective cilia exhibit immobility or dyskinetic movement, resulting in significantly slower CSF flow in Tmem216 mutants than controls. In addition to aberrant ciliogenesis and ciliary dysfunction, Tmem216 ablation disrupts both translational polarity (asymmetric positioning of cilia on the apical area) in RGCs and ECs, as well as rotational polarity (unidirectional orientation of basal bodies within individual ECs and intercellular rotational alignment of motile cilia) in ECs. These findings identify TMEM216 as a critical TZ protein essential for ciliogenesis during ependymal development and establishing ependymal planar cell polarity.
- 10 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (37)
Open AccessTmem216 deficiency induces hydrocephalus via impaired ciliogenesis and disrupted ependymal planar polarity in mice
Defects in multiciliated ependymal cells (ECs), which line the cerebral ventricular walls and generate unidirectional cerebrospinal fluid (CSF) flow through coordinated ciliary beating, can lead to CSF accumulation and hydrocephalus. TMEM216 , a ciliopathy-associated gene mutated in Joubert, Meckel, and related syndromes, encodes an essential component of the protein complexes that form the transition zone (TZ) at the base of primary cilia. Here, we demonstrate that central nervous system-specific inactivation of Tmem216 results in severe postnatal hydrocephalus. TMEM216 localizes to the TZ of motile cilia in ECs and the TZ of primary cilia in radial glia cells (RGCs), the embryonic precursors of ECs. While Tmem216 -deficient ECs differentiate normally, TZ structure and ciliogenesis in both ECs and RGCs are severely disrupted, as shown by reduced cilia abundance and disrupted ciliary ultrastructure. These defective cilia exhibit immobility or dyskinetic movement, resulting in significantly slower CSF flow in Tmem216 mutants than controls. In addition to aberrant ciliogenesis and ciliary dysfunction, Tmem216 ablation disrupts both translational polarity (asymmetric positioning of cilia on the apical area) in RGCs and ECs, as well as rotational polarity (unidirectional orientation of basal bodies within individual ECs and intercellular rotational alignment of motile cilia) in ECs. These findings identify TMEM216 as a critical TZ protein essential for ciliogenesis during ependymal development and establishing ependymal planar cell polarity.
- Open Access
- 1 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
TMEM216 inhibits breast cancer lung metastasis by modulating IGF1R-IRS4 signaling pathway
Breast cancer (BC) metastasis remains a major cause of mortality, yet the molecular mechanisms driving this process are incompletely understood. This study identifies TMEM216, a transmembrane protein implicated in ciliary homeostasis, as a suppressor of lung metastasis in BC. Using mammary-specific Tmem216 knockout mice, we demonstrate that Tmem216 deficiency promotes lung metastasis without affecting primary tumor proliferation. Clinical analyses reveal reduced TMEM216 expression in metastatic lesions and aggressive cell lines, correlating with poor patient distant metastasis-free survival. Mechanistically, TMEM216 interacts with IGF1R and binds to IRS4 via the conserved K79-D1049 interaction, disrupting the IGF1R-IRS4 complex formation and suppressing IGF pathway activation. Rescue experiments in vitro and in vivo confirm that TMEM216-mediated metastasis inhibition depends on IGF signaling modulation. Tissue microarray analyses further establish an inverse correlation between TMEM216 levels and IGF1R phosphorylation in BC patients, with low TMEM216 expression associated with advanced metastasis. These findings delineate TMEM216 as a critical regulator of the IGF1R-IRS4 axis, offering therapeutic opportunities for targeting metastatic BC.
- 1 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTMEM216 inhibits breast cancer lung metastasis by modulating IGF1R-IRS4 signaling pathway
Breast cancer (BC) metastasis remains a major cause of mortality, yet the molecular mechanisms driving this process are incompletely understood. This study identifies TMEM216, a transmembrane protein implicated in ciliary homeostasis, as a suppressor of lung metastasis in BC. Using mammary-specific Tmem216 knockout mice, we demonstrate that Tmem216 deficiency promotes lung metastasis without affecting primary tumor proliferation. Clinical analyses reveal reduced TMEM216 expression in metastatic lesions and aggressive cell lines, correlating with poor patient distant metastasis-free survival. Mechanistically, TMEM216 interacts with IGF1R and binds to IRS4 via the conserved K79-D1049 interaction, disrupting the IGF1R-IRS4 complex formation and suppressing IGF pathway activation. Rescue experiments in vitro and in vivo confirm that TMEM216-mediated metastasis inhibition depends on IGF signaling modulation. Tissue microarray analyses further establish an inverse correlation between TMEM216 levels and IGF1R phosphorylation in BC patients, with low TMEM216 expression associated with advanced metastasis. These findings delineate TMEM216 as a critical regulator of the IGF1R-IRS4 axis, offering therapeutic opportunities for targeting metastatic BC.
- Open Access
- 15 December 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 528
BEX2 regulates autophagy by inhibiting PIK3CA-p85 interaction in non-small-cell lung cancer cells
Autophagy is an evolutionarily conserved cellular process that maintains homeostasis. It enables tumor cells to survive and grow, which may lead to drug resistance. The PI3K/AKT/mTOR pathway is reported to play a key role in autophagy induction. BEX2 promotes cell growth and survival in cancer cells. However, its role in autophagy remains unclear. Human non-small cell lung cancer (NSCLC) cell lines (A549, H1792 and H1299) and 293FT cells were used to investigate the function of BEX2 in autophagy. The experimental research was conducted via western blot, co-immunoprecipitation and confocal microscopy. Our data show that rapamycin induces BEX2 protein levels. Western blot and confocal microscopy analysis demonstrate that BEX2 regulates autophagy. Furthermore, BEX2 impairs PI3K/AKT/mTOR signaling. Specifically, BEX2 interacts with PIK3CA (PI3K catalytic subunit). BEX2 impairs the interaction of PIK3CA and p85 (PI3K regulatory subunit), therefore inhibiting PI3K activity. In summary, BEX2 regulates autophagy through the PI3K/AKT/mTOR signaling pathway by modulating the activity of PI3K, specifically dependent on the presence of PIK3CA. We discovered that BEX2 promotes autophagic flux via PI3K/AKT/mTOR signaling. BEX2 interacts with PIK3CA and impairs PIK3CA and p85 interaction, which hinders activation of PI3K/AKT/mTOR signaling and promotes autophagy induction.
- 15 December 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 528
Open AccessBEX2 regulates autophagy by inhibiting PIK3CA-p85 interaction in non-small-cell lung cancer cells
Autophagy is an evolutionarily conserved cellular process that maintains homeostasis. It enables tumor cells to survive and grow, which may lead to drug resistance. The PI3K/AKT/mTOR pathway is reported to play a key role in autophagy induction. BEX2 promotes cell growth and survival in cancer cells. However, its role in autophagy remains unclear. Human non-small cell lung cancer (NSCLC) cell lines (A549, H1792 and H1299) and 293FT cells were used to investigate the function of BEX2 in autophagy. The experimental research was conducted via western blot, co-immunoprecipitation and confocal microscopy. Our data show that rapamycin induces BEX2 protein levels. Western blot and confocal microscopy analysis demonstrate that BEX2 regulates autophagy. Furthermore, BEX2 impairs PI3K/AKT/mTOR signaling. Specifically, BEX2 interacts with PIK3CA (PI3K catalytic subunit). BEX2 impairs the interaction of PIK3CA and p85 (PI3K regulatory subunit), therefore inhibiting PI3K activity. In summary, BEX2 regulates autophagy through the PI3K/AKT/mTOR signaling pathway by modulating the activity of PI3K, specifically dependent on the presence of PIK3CA. We discovered that BEX2 promotes autophagic flux via PI3K/AKT/mTOR signaling. BEX2 interacts with PIK3CA and impairs PIK3CA and p85 interaction, which hinders activation of PI3K/AKT/mTOR signaling and promotes autophagy induction.
- Open Access
- 12 March 2025
- Published by Springer Nature in Research Square
TMEM216 inhibits breast cancer lung metastasis by modulating IGF1R-IRS4 signaling pathway
Breast cancer (BrCa) metastasis remains a major cause of mortality, yet the molecular mechanisms driving this process are incompletely understood. This study identifies TMEM216, a transmembrane protein implicated in ciliary homeostasis, as a novel suppressor of lung metastasis in BrCa. Using mammary-specific Tmem216 knockout mice, we demonstrate that Tmem216 deficiency promotes lung metastasis without affecting primary tumor proliferation. Clinical analyses reveal reduced TMEM216 expression in metastatic lesions and aggressive cell lines, correlating with poor patient distant metastasis-free survival. Mechanistically, TMEM216 interacts with IGF1R and binds to IRS4 via the conserved K79-D1049 interaction, disrupting the IGF1R-IRS4 complex formation and suppressing IGF pathway activation. Rescue experiments in vitro and in vivo confirm that TMEM216-mediated metastasis inhibition depends on IGF signaling modulation. Tissue microarray analyses further establish an inverse correlation between TMEM216 levels and IGF1R phosphorylation in BrCa patients, with low TMEM216 expression associated with advanced metastasis. These findings delineate TMEM216 as a critical regulator of the IGF1R-IRS4 axis, offering therapeutic opportunities for targeting metastatic BrCa.
- 12 March 2025
- Published by Springer Nature in Research Square
Open AccessTMEM216 inhibits breast cancer lung metastasis by modulating IGF1R-IRS4 signaling pathway
Breast cancer (BrCa) metastasis remains a major cause of mortality, yet the molecular mechanisms driving this process are incompletely understood. This study identifies TMEM216, a transmembrane protein implicated in ciliary homeostasis, as a novel suppressor of lung metastasis in BrCa. Using mammary-specific Tmem216 knockout mice, we demonstrate that Tmem216 deficiency promotes lung metastasis without affecting primary tumor proliferation. Clinical analyses reveal reduced TMEM216 expression in metastatic lesions and aggressive cell lines, correlating with poor patient distant metastasis-free survival. Mechanistically, TMEM216 interacts with IGF1R and binds to IRS4 via the conserved K79-D1049 interaction, disrupting the IGF1R-IRS4 complex formation and suppressing IGF pathway activation. Rescue experiments in vitro and in vivo confirm that TMEM216-mediated metastasis inhibition depends on IGF signaling modulation. Tissue microarray analyses further establish an inverse correlation between TMEM216 levels and IGF1R phosphorylation in BrCa patients, with low TMEM216 expression associated with advanced metastasis. These findings delineate TMEM216 as a critical regulator of the IGF1R-IRS4 axis, offering therapeutic opportunities for targeting metastatic BrCa.
- 23 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (820) , eabo0465
TMEM216 promotes primary ciliogenesis and Hedgehog signaling through the SUFU-GLI2/GLI3 axis
Primary cilia are enriched in signaling receptors, and defects in their formation or function can induce conditions such as polycystic kidney disease, postaxial hexadactyly, and microphthalmia. Mammalian Hedgehog (Hh) signaling is important in the development of primary cilia, and TMEM216, a transmembrane protein that localizes to the base of cilia, is also implicated in ciliogenesis in zebrafish. Here, we found thatTmem216-deficient mice had impaired Hh signaling and displayed typical ciliopathic phenotypes. These phenomena were also observed in cells deficient in TMEM216. Furthermore, TMEM216 interacted with core Hh signaling proteins, including SUFU, a negative regulator of Hh, and GLI2/GLI3, transcription factors downstream of Hh. The competition between TMEM216 and SUFU for binding to GLI2/GLI3 inhibited the cleavage of GLI2/GLI3 into their repressor forms, which resulted in the nuclear accumulation of full-length GLI2 and the decreased nuclear localization of cleaved GLI3, ultimately leading to the activation of Hh signaling. Together, these data suggest that the TMEM216-SUFU-GLI2/GLI3 axis plays a role in TMEM216 deficiency–induced ciliopathies and Hh signaling abnormalities.
- 23 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (820) , eabo0465
TMEM216 promotes primary ciliogenesis and Hedgehog signaling through the SUFU-GLI2/GLI3 axis
Primary cilia are enriched in signaling receptors, and defects in their formation or function can induce conditions such as polycystic kidney disease, postaxial hexadactyly, and microphthalmia. Mammalian Hedgehog (Hh) signaling is important in the development of primary cilia, and TMEM216, a transmembrane protein that localizes to the base of cilia, is also implicated in ciliogenesis in zebrafish. Here, we found thatTmem216-deficient mice had impaired Hh signaling and displayed typical ciliopathic phenotypes. These phenomena were also observed in cells deficient in TMEM216. Furthermore, TMEM216 interacted with core Hh signaling proteins, including SUFU, a negative regulator of Hh, and GLI2/GLI3, transcription factors downstream of Hh. The competition between TMEM216 and SUFU for binding to GLI2/GLI3 inhibited the cleavage of GLI2/GLI3 into their repressor forms, which resulted in the nuclear accumulation of full-length GLI2 and the decreased nuclear localization of cleaved GLI3, ultimately leading to the activation of Hh signaling. Together, these data suggest that the TMEM216-SUFU-GLI2/GLI3 axis plays a role in TMEM216 deficiency–induced ciliopathies and Hh signaling abnormalities.
- Open Access
- 30 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-15
Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells
Brain expressed X-linked gene 2 (BEX2) encoded protein was originally identified to promote transcription by interacting with several transcription factors in the DNA–binding complexes. Recently, BEX2 was found to be localized in cytosol and/or mitochondria and regulate apoptosis in cancer cells and tumor growth. However, the molecular mechanism underlying its roles in cancer cells remains unclear. Here, we report that crotonylated BEX2 plays an important role in inhibiting chemotherapeutic agent-induced apoptosis via enhancing mitophagy in human lung cancer cells. BEX2 promotes mitophagy by facilitating interaction between NDP52 and LC3B. Moreover, BEX2 crotonylation at K59 is critical in the BEX2-mediated mitophagy in lung cancer cells. The K59R mutation of BEX2 inhibits mitophagy by affecting the interaction of NDP52 and LC3B. BEX2 expression is elevated after anticancer drug treatment, and its overexpression inhibits chemotherapy-induced apoptosis. In addition, inhibition of BEX2-regulated mitophagy sensitizes tumor cells to apoptosis. Furthermore, BEX2 promotes tumor growth and inhibits apoptosis by regulating mitophagy in vivo. We also confirm that BEX2 is overexpressed in lung adenocarcinoma and is associated with poor prognosis in lymph node metastasis-free cancer. Therefore, combination treatment with pharmaceutical approaches targeting BEX2-induced mitophagy and anticancer drugs may represent a potential strategy for NSCLC therapy.
- 30 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-15
Open AccessCrotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells
Brain expressed X-linked gene 2 (BEX2) encoded protein was originally identified to promote transcription by interacting with several transcription factors in the DNA–binding complexes. Recently, BEX2 was found to be localized in cytosol and/or mitochondria and regulate apoptosis in cancer cells and tumor growth. However, the molecular mechanism underlying its roles in cancer cells remains unclear. Here, we report that crotonylated BEX2 plays an important role in inhibiting chemotherapeutic agent-induced apoptosis via enhancing mitophagy in human lung cancer cells. BEX2 promotes mitophagy by facilitating interaction between NDP52 and LC3B. Moreover, BEX2 crotonylation at K59 is critical in the BEX2-mediated mitophagy in lung cancer cells. The K59R mutation of BEX2 inhibits mitophagy by affecting the interaction of NDP52 and LC3B. BEX2 expression is elevated after anticancer drug treatment, and its overexpression inhibits chemotherapy-induced apoptosis. In addition, inhibition of BEX2-regulated mitophagy sensitizes tumor cells to apoptosis. Furthermore, BEX2 promotes tumor growth and inhibits apoptosis by regulating mitophagy in vivo. We also confirm that BEX2 is overexpressed in lung adenocarcinoma and is associated with poor prognosis in lymph node metastasis-free cancer. Therefore, combination treatment with pharmaceutical approaches targeting BEX2-induced mitophagy and anticancer drugs may represent a potential strategy for NSCLC therapy.
- Open Access
DIRAS3 enhances RNF19B-mediated RAC1 ubiquitination and degradation in non-small-cell lung cancer cells
- Open Access
- 21 April 2023
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 21 (1) , 1-15
Gasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells
Background: Lung cancer is the most lethal malignancy, with non-small cell lung cancer (NSCLC) being the most common type (~ 85%). Abnormal activation of epidermal growth factor receptor (EGFR) promotes the development of NSCLC. Chemoresistance to tyrosine kinase inhibitors, which is elicited by EGFR mutations, is a key challenge for NSCLC treatment. Therefore, more thorough understanding of EGFR expression and dynamics are needed. Methods: Human non-small cell lung cancer cells and HEK293FT cells were used to investigate the molecular mechanism of gasdermin E (GSDME) regulating EGFR stability by Western blot analysis, immunoprecipitation and immunofluorescence. GSDME and EGFR siRNAs or overexpression plasmids were used to characterize the functional role of GSDME and EGFR in vitro. EdU incorporation, CCK-8 and colony formation assays were used to determine the proliferation ability of non-small cell lung cancer cells. Results: GSDME depletion reduced the proliferation of non-small cell lung cancer cells in vitro. Importantly, both GSDME-full length (GSDME-FL) and GSDME-N fragment physically interacted with EGFR. GSDME interacted with cytoplasmic fragment of EGFR. GSDME knockdown inhibited EGFR dimerization and phosphorylation at tyrosine 1173 (EGFRY1173), which activated ERK1/2. GSDME knockdown also promoted phosphorylation of EGFR at tyrosine 1045 (EGFRY1045) and its degradation. Conclusion: These results indicate that GSDME-FL increases the stability of EGFR, while the GSDME N-terminal fragment induces EGFR degradation. The GSDME-EGFR interaction plays an important role in non-small cell lung cancer development, reveal a previously unrecognized link between GSDME and EGFR stability and offer new insight into cancer pathogenesis.
- 21 April 2023
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 21 (1) , 1-15
Open AccessGasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells
Background: Lung cancer is the most lethal malignancy, with non-small cell lung cancer (NSCLC) being the most common type (~ 85%). Abnormal activation of epidermal growth factor receptor (EGFR) promotes the development of NSCLC. Chemoresistance to tyrosine kinase inhibitors, which is elicited by EGFR mutations, is a key challenge for NSCLC treatment. Therefore, more thorough understanding of EGFR expression and dynamics are needed. Methods: Human non-small cell lung cancer cells and HEK293FT cells were used to investigate the molecular mechanism of gasdermin E (GSDME) regulating EGFR stability by Western blot analysis, immunoprecipitation and immunofluorescence. GSDME and EGFR siRNAs or overexpression plasmids were used to characterize the functional role of GSDME and EGFR in vitro. EdU incorporation, CCK-8 and colony formation assays were used to determine the proliferation ability of non-small cell lung cancer cells. Results: GSDME depletion reduced the proliferation of non-small cell lung cancer cells in vitro. Importantly, both GSDME-full length (GSDME-FL) and GSDME-N fragment physically interacted with EGFR. GSDME interacted with cytoplasmic fragment of EGFR. GSDME knockdown inhibited EGFR dimerization and phosphorylation at tyrosine 1173 (EGFRY1173), which activated ERK1/2. GSDME knockdown also promoted phosphorylation of EGFR at tyrosine 1045 (EGFRY1045) and its degradation. Conclusion: These results indicate that GSDME-FL increases the stability of EGFR, while the GSDME N-terminal fragment induces EGFR degradation. The GSDME-EGFR interaction plays an important role in non-small cell lung cancer development, reveal a previously unrecognized link between GSDME and EGFR stability and offer new insight into cancer pathogenesis.
- Open Access
- 12 February 2022
- Published by Elsevier in Geoscience Frontiers
- Vol. 13 (3) , 101370
Understanding the spatial representativeness of air quality monitoring network and its application to PM2.5 in the mainland China
- 12 February 2022
- Published by Elsevier in Geoscience Frontiers
- Vol. 13 (3) , 101370
Open AccessUnderstanding the spatial representativeness of air quality monitoring network and its application to PM2.5 in the mainland China
- Open Access
- 28 July 2021
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 19 (1) , 1-12
Hhex inhibits cell migration via regulating RHOA/CDC42-CFL1 axis in human lung cancer cells
Background: Hhex(human hematopoietically expressed homeobox), also known as PRH, is originally considered as a transcription factor to regulate gene expression due to its homebox domain. Increasing studies show that Hhex plays a significant role in development, including anterior–posterior axis formation, vascular development and HSCs self-renewal etc. Hhex is linked to many diseases such as cancers, leukemia, and type-2 diabetes. Although Hhex is reported to inhibit cell migration and invasion of breast and prostate epithelial cells by upregulating Endoglin expression, the effect and molecular mechanism for lung cancer cell motility regulation remains elusive. Methods: Human non-small cell lung cancer cells and HEK293FT cells were used to investigate the molecular mechanism of Hhex regulating lung cancer cell migration by using Western blot, immunoprecipitation, wound-healing scratch assay, laser confocal. Results: Our data indicated that Hhex could inhibit cell migration and cell protrusion formation in lung cancer cells. In addition, Hhex inhibited CFL1 phosphorylation to keep its F-actin-severing activity. RHOGDIA was involved in Hhex-induced CFL1 phosphorylation regulation. Hhex enhanced RHOGDIA interaction with RHOA/CDC42, thus maintaining RHOA/CDC42 at an inactive form. Conclusion: Collectively, these data indicate that Hhex inhibited the activation of RHOA/CDC42 by enhancing interaction of RHOGDIA with RHOA/CDC42, and then RHOA/ CDC42-p-CFL1 signaling pathway was blocked. Consequently, the formation of Filopodium and Lamellipodium on the cell surface was suppressed, and thus the ability of lung cancer cells to migrate was decreased accordingly. Our findings show Hhex plays an important role in regulating migration of lung cancer cells and may provide a potential target for lung cancer therapy.
- 28 July 2021
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 19 (1) , 1-12
Open AccessHhex inhibits cell migration via regulating RHOA/CDC42-CFL1 axis in human lung cancer cells
Background: Hhex(human hematopoietically expressed homeobox), also known as PRH, is originally considered as a transcription factor to regulate gene expression due to its homebox domain. Increasing studies show that Hhex plays a significant role in development, including anterior–posterior axis formation, vascular development and HSCs self-renewal etc. Hhex is linked to many diseases such as cancers, leukemia, and type-2 diabetes. Although Hhex is reported to inhibit cell migration and invasion of breast and prostate epithelial cells by upregulating Endoglin expression, the effect and molecular mechanism for lung cancer cell motility regulation remains elusive. Methods: Human non-small cell lung cancer cells and HEK293FT cells were used to investigate the molecular mechanism of Hhex regulating lung cancer cell migration by using Western blot, immunoprecipitation, wound-healing scratch assay, laser confocal. Results: Our data indicated that Hhex could inhibit cell migration and cell protrusion formation in lung cancer cells. In addition, Hhex inhibited CFL1 phosphorylation to keep its F-actin-severing activity. RHOGDIA was involved in Hhex-induced CFL1 phosphorylation regulation. Hhex enhanced RHOGDIA interaction with RHOA/CDC42, thus maintaining RHOA/CDC42 at an inactive form. Conclusion: Collectively, these data indicate that Hhex inhibited the activation of RHOA/CDC42 by enhancing interaction of RHOGDIA with RHOA/CDC42, and then RHOA/ CDC42-p-CFL1 signaling pathway was blocked. Consequently, the formation of Filopodium and Lamellipodium on the cell surface was suppressed, and thus the ability of lung cancer cells to migrate was decreased accordingly. Our findings show Hhex plays an important role in regulating migration of lung cancer cells and may provide a potential target for lung cancer therapy.